Asian Pacific Journal of Cancer Prevention

  • 제15권14호
  • /
  • Pages.5653-5657
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes

  • 발행 : 2014.07.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: To evaluate factors which effect treatment interruption during concurrent chemoradiotherapy (CCRT) and overall survival in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital. Materials and Methods: Between January 2006 and December 2007, 107 patients with stage IB2-IVA as FIGO staging, 2000, were treated with CCRT in Srinagarind Hospital. Factors which caused treatment interruptions and impacted on overall survival were reviewed and analyzed. Results: Twenty of 107 patients had treatment interruption during CCRT in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital. The causes of treatment interruption were as follows: hematologic toxicity was found in 16 of 20 cases, 12 cases with grade 2 and 4 cases with grade 3; three of 20 cases had gastrointestinal toxicities, 1 case with grade 2 and 2 cases with grade 3; one case had grade 3 skin toxicity. The mean total treatment time of the uninterrupted and interrupted groups were significantly different (78.98 days vs 161.80 days, p <0.001). The patients who could tolerate ${\geq}5$ cycles of cisplatin administration had significantly higher mean white blood counts (WBC) ($9,769cells/mm^3$ vs $7,141cells/mm^3$, p=0.02). The mean initial hemoglobin (Hb) in the uninterrupted group was significantly higher than the interrupted group (11.5 mg% vs 10.3 mg%, p=0.03). Other factors including age, KPS, initial platelets, initial serum creatinine levels showed no statistical significance. The 3-year overall survival of the uninterrupted group was better than in the interrupted group (78.6% vs 55.0%, p=0.03). Conclusions: The initial Hb and WBC levels were significantly correlated with treatment interruption during CCRT in patients with uterine cervical cancer. The 3-year overall survival of the uninterrupted group was significantly better than interrupted group. These factors may then be used indirectly to predict the outcomes of treatment.

키워드

참고문헌

  1. Arai T, NakanoT, Morita S, et al (1992). High dose rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. A 20-year experience. Cancer, 69, 175-180. https://doi.org/10.1002/1097-0142(19920101)69:1<175::AID-CNCR2820690129>3.0.CO;2-B
  2. Berraho M, Najdi A, Mathoulin-Pelissier S, et al (2012). Direct costs of cervical cancer management in Morocco. Asian Pac J Cancer Prev, 13, 3159-63. https://doi.org/10.7314/APJCP.2012.13.7.3159
  3. Cancer Unit, Khon Kaen University, Statistical report (2008), Khon Kaen: Tumor Registry, Cancer Unit, Khon Kaen University, 5.
  4. Deerasamee S, Srivatanakul P, (1999). Cervix uteri, In: Deerasamee S, Martin N, Sontipong S, Sriamporn S, Sriplung S, Srivatanakul P, (eds). Cancer in Thailand 1992- 1994. 2: Lyon: IARC, 56-9.
  5. Benedet JL, Bender H, Jones H, et al (2000). FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet, 70, 209-62. https://doi.org/10.1016/S0020-7292(00)90001-8
  6. Green JA, Kirwan JM, Tierney JF, et al (2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet, 358, 781-6. https://doi.org/10.1016/S0140-6736(01)05965-7
  7. Intaraphet S, Kasatpibal N, Siriaunkgul S, et al (2013). Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev, 14, 5355-60. https://doi.org/10.7314/APJCP.2013.14.9.5355
  8. Kirwan JM, Symonds P, Green JA, et al (2003). A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol, 68, 217-26. https://doi.org/10.1016/S0167-8140(03)00197-X
  9. Lorvidhaya V, Tonusin A, Changwiwit W, et al (2000). High dose rate afterloading brachytherapy in carcinomas of the cervix: an experience of 1992 patients. Int J Radiat Oncol Biol Phys, 46, 1185-91. https://doi.org/10.1016/S0360-3016(99)00383-1
  10. McArdle O, Kigula-Mugambe JB (2007). Contraindications to cisplatin based chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa. Radiother Oncol, 83, 94-6. https://doi.org/10.1016/j.radonc.2007.02.006
  11. Monk BJ, Tian C, Rose PG, et al (2007). Which clinical / pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol, 105, 427-33. https://doi.org/10.1016/j.ygyno.2006.12.027
  12. National Cancer Institute Clinical Announcement on Cervical Cancer, February 22, 1999. http://www.nci.nih.gov/ clinicaltrials/digestpage/cervical-cancer-
  13. Nugent EK, Case AS, Hoff JT, et al (2010). Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol, 116, 438-41. https://doi.org/10.1016/j.ygyno.2009.09.045
  14. Obermair A, Cheuk R, Horwood K, et al (2003). Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. Int J Gynecol Cancer, 13, 633-9. https://doi.org/10.1046/j.1525-1438.2003.13395.x
  15. Perez CA, Grigsby PW, Castro-Vita H, et al (1995). Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys, 32, 1275-88. https://doi.org/10.1016/0360-3016(95)00220-S
  16. Pesee M, Tangvoraphonkchai V, Reamsiri T, et al (1995). Low dose rate brachytherapy Caesium -137 afterloading in the treatment of carcinoma of uterine cervix in Srinagarind hospital: Analysis of a actuarial survival rate. Thai J Radiol, 1, 125-30.
  17. Pesee M, Krusun S, Padoongcharoen P (2010). High dose rate cobalt-60 afterloading intracavitary therapy of the uterine cervical carcinoma in Srinagarind hospital, Analysis of survival. Asian Pac J Cancer Prev, 11, 1469-71.
  18. Pesee M, Kirdpon K, Puapairoj A, Kirdpon S, Prathanadi P (2013). Palliative treatment of advanced cervical cancer with radiotherapy and Thai herbal medicine as supportive remedy, analysis of survival. Asian Pac J Cancer Prev, 14, 1593-6. https://doi.org/10.7314/APJCP.2013.14.3.1593
  19. Petereit DG, Sarkaria JN, Chappell R, et al (1995). The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys, 32, 1301-7. https://doi.org/10.1016/0360-3016(94)00635-X
  20. Pomros P, Sriamporn S, Tangvoraphonkchai V, et al (2007). Factors affectng survival of cervical cancer patients treated at the radiation unit of Srinarind Hospital, Khon Kaen University, Thailand. Asian Pac J Cancer Prev, 8, 297-300.
  21. Potter R, Georg P, Dimopoulos JCA, et al (2011). Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol, 100, 116-23. https://doi.org/10.1016/j.radonc.2011.07.012
  22. Rose PG (2000). Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs, 60, 1239-44. https://doi.org/10.2165/00003495-200060060-00001
  23. Talaiezadeh A, Tabesh H, Sattari A, et al (2013). Cancer incidence in Southwest of Iran: First report from Khuzestan population-based cancer registry, 2002-2009. Asian Pac J Cancer Prev, 13, 7517-22. https://doi.org/10.7314/APJCP.2013.14.12.7517
  24. Tungsubutra K, Pesi M, Tangvoraphonkchai V (1985). Problems in treatment of cancer in the rural areas and the remedies. In Mould RF, Tungsubutra K, eds. Diagnosis and treatment of carcinoma of the cervix in developing areas; Bristol and Boston, Adam Hilger, 219-22.
  25. Utada M, Ohno Y, Shimizu S, Ito Y, Tsukuma H (2012). Cancer incidence and mortality in Osaka, Japan: Future trends estimation with an age-period-cohort model. Asian Pac J Cancer Prev, 13, 3893-98. https://doi.org/10.7314/APJCP.2012.13.8.3893
  26. Wong FCS, Tung SY, Leung T-W, et al (2003). Treatment results of high-dose rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens. Int J Radiation Oncology Biol phys. 55, 1254-64. https://doi.org/10.1016/S0360-3016(02)04525-X

피인용 문헌

  1. Association of Educational Levels with Survival in Indian Patients with Cancer of the Uterine Cervix vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3121
  2. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3827
  3. Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer vol.97, pp.30, 2018, https://doi.org/10.1097/MD.0000000000011592
  4. Acute radiation toxicity during and after concurrent chemoradiotherapy in patients with localy advanced cervical cancer vol.10, pp.2, 2018, https://doi.org/10.5937/racter10-18049